Abstract
Background Angelman syndrome (AS) is a rare genetic condition characterised by global developmental delay, including severe to profound intellectual disability. The parents of persons with AS experience increased stress, anxiety and depression. This impacts parents’ career choices and productivity.
Aims To estimate, for the first time, the total productivity lost by the parents of persons with AS over a 10-year period in Australia and the corresponding cost to society.
Methods and procedures A cost-of-illness model with simulated follow-up over a 10-year period was developed, with 2019 as the baseline year, facilitated by a Markov chain of life tables. The prevalence of persons with AS and their parents, the productivity-adjusted life years (PALYs) lost by parents, and the cost to society were estimated. Key data were obtained from a prospective cohort of AS families, peer-reviewed literature, and publicly available sources.
Outcomes and results The base-case productivity burden borne by the estimated 330 living parents of the 428 prevalent-persons with AS totalled AUD$45.30 million, corresponding to a loss of 38.42% of PALYs per-parent.
Conclusions and implications Caring for a child with AS has a significant impact on the productivity of affected parents, with a large associated impact on the broader Australian economy.
What this paper adds?Persons with AS require lifelong care and support. Consequently, AS results in a significant socioeconomic impact, borne both by the healthcare system and affected families. This is the first known study to estimate the total impact of caring for a child with AS on parental productivity, as well as the first study known to estimate the PALYs lost by a parental or caregiver population. This study found that caring for a child with AS has a significant impact on the productivity of affected parents, with a large associated impact on the broader Australian economy. At present, the supports available to persons with AS and their families include sleep aids and behavioural therapy. In future, specific therapeutic treatments for AS may become available, with trials underway at present investigating the efficacy and effectiveness of gene therapies for AS. As such, evidence regarding the total socioeconomic impact, including the parental productivity burden, attributable to AS is needed to inform future funding decisions.
Competing Interest Statement
E.K.B. and D.E.G. have received funding from the Foundation for Angelman Syndrome Therapeutics (FAST, Australia). The authors report that they have no other conflicts or competing interests relevant to the contents of this paper to disclose.
Funding Statement
This study was supported by the Victorian Government's Operational Infrastructure Support Program; Next Generation Clinical Researchers Program - Career Development Fellowship, funded by the Medical Research Future Fund (MRF1141334 to D.E.G.); and the Foundation for Angelman Syndrome Therapeutics (FAST, Australia to E.K.B. and D.E.G.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Royal Children's Hospital Human Research Ethics Committee (reference number 33066) and the Monash University Human Research Ethics Committee (reference number 2021-25930-55113). All parents/caregivers provided written informed consent and participants who were deemed cognitively able also provided written informed consent. The authors certify that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
This version of the manuscript has been revised to incorporate a more contemporary prevalence estimate which was not previously available.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
Abbreviations
- AS
- Angelman syndrome
- CHEERS
- Consolidated Health Economic Evaluation Reporting Standards
- CSRI
- Client Service Receipt Inventory
- DS
- Dravet syndrome
- FTE
- full-time equivalent
- PALY
- productivity-adjusted life year
- PDMA
- Participant Developmental and Medical Anamnesis
- WPAI
- Work Productivity and Activity Impairment
